DCM
DNTH icon

Driehaus Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Driehaus Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.6M Buy
+317,312
New +$18.4M 0.2% 164
2021
Q3 		– Sell
-5,000
Closed -$782K – 410
2021
Q2 		$782K Buy
+5,000
New +$918K 0.01% 354

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Driehaus Capital Management's DNTH Position: Q1 2026 in Review

Driehaus Capital Management opened a new position in Dianthus Therapeutics (DNTH) in Q1 2026: 317,312 shares worth $26.6M. The stake represents 0.2% of the portfolio and ranks #164 among its holdings. This is a return to the name: Driehaus Capital Management previously reported a position in DNTH as recently as Q2 2021.

Driehaus Capital Management first reported a position in DNTH in Q2 2021 and has held it in 2 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Driehaus Capital Management held 317,312 shares of Dianthus Therapeutics worth $26.6M as of Q1 2026.
  • Dianthus Therapeutics was a new Driehaus Capital Management position in Q1 2026.
  • Dianthus Therapeutics made up 0.2% of Driehaus Capital Management's portfolio in Q1 2026, its #164 holding.
  • Driehaus Capital Management first reported a position in Dianthus Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.